Comprehensive Analysis of Shared Risk Genes and Immunity-metabolisms Between Non-alcoholic Fatty Liver Disease and Atherosclerosis Via Bulk and Single-cell Transcriptome Analyses

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Aug 21

PMID 39165965

Authors

Qian Hu

Yunfang Luo

Hao He

Hua Chen

Di Liao

Affiliations

Soon will be listed here.

Abstract

Objective: and design: Considering the clinical link between non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (AS), we performed bioinformatics analysis to uncover their pathogenic interrelationship.

Methods And Results: Data from the U.S. National Health and Nutritional Examination Survey (NHANES) 1999-2018 were included. Among 4851 participants in NHANES, NAFLD was significantly associated with atherosclerotic cardiovascular disease risk (ASCVD risk) (OR = 2.32, 95%CI: 2.04-2.65, P < 0.0001). We conducted WGCNA analysis for NAFLD (GSE130970) and AS (GSE28829) and identified three modules positively related to NAFLD severity and two modules accelerating atherosclerosis plaque progression. 198 key-modules genes were obtained via overlapping these modules. Next, we mined the disease-controlled differentially expressed genes (DEGs) from NAFLD (GSE89632) and AS (GSE100927), respectively. The final common risk genes (, , , , , , and ) were defined by intersecting the upregulated DEGs with 198 genes and validated in new datasets (GSE48452 and GSE43292). Importantly, they showed good diagnostic ability for NAFLD and AS. Immune infiltration analysis showed both illnesses have dysregulated immunity. Analysis of single-cell sequencing datasets NAFLD (GSE179886) and AS (GSE159677) uncovered different abnormal expressions of seven common genes in different immune cells while highlighting metabolic disturbances including upregulation of fatty acid biosynthesis, downregulation of fatty acid degradation and elongation.

Conclusion: We found 7 shared hub genes with good diagnostic ability and depicted the landscapes of immune and metabolism involved in NAFLD and AS. Our results provided a comprehensive association between them and may contribute to developing potential intervention strategies for targeting both disorders based on these risk factors.

References

Wu X, Xu M, Geng M, Chen S, Little P, Xu S . Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies. Signal Transduct Target Ther. 2023; 8(1):220. PMC: 10224996. DOI: 10.1038/s41392-023-01439-y. View

Younossi Z, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N . Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2019; 69(3):564-568. DOI: 10.1136/gutjnl-2019-318813. View

Huang Y, Wang L, Mao Y, Nan G . Long Noncoding RNA-H19 Contributes to Atherosclerosis and Induces Ischemic Stroke via the Upregulation of Acid Phosphatase 5. Front Neurol. 2019; 10:32. PMC: 6369351. DOI: 10.3389/fneur.2019.00032. View

Tan Y, Liu X, Zhou K, He X, Lu C, He B . The Potential Biomarkers to Identify the Development of Steatosis in Hyperuricemia. PLoS One. 2016; 11(2):e0149043. PMC: 4758628. DOI: 10.1371/journal.pone.0149043. View

Libby P . The changing landscape of atherosclerosis. Nature. 2021; 592(7855):524-533. DOI: 10.1038/s41586-021-03392-8. View

Abdolmaleki F, Gheibi Hayat S, Bianconi V, Johnston T, Sahebkar A . Atherosclerosis and immunity: A perspective. Trends Cardiovasc Med. 2018; 29(6):363-371. DOI: 10.1016/j.tcm.2018.09.017. View

Ficht X, Iannacone M . Immune surveillance of the liver by T cells. Sci Immunol. 2020; 5(51). DOI: 10.1126/sciimmunol.aba2351. View

Arai T, Atsukawa M, Tsubota A, Kato K, Abe H, Ono H . Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep. 2021; 11(1):15938. PMC: 8342487. DOI: 10.1038/s41598-021-95581-8. View

Sacks D, Baxter B, Campbell B, Carpenter J, Cognard C, Dippel D . Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018; 13(6):612-632. DOI: 10.1177/1747493018778713. View

10.

Davis A, Grondin C, Johnson R, Sciaky D, Wiegers J, Wiegers T . Comparative Toxicogenomics Database (CTD): update 2021. Nucleic Acids Res. 2020; 49(D1):D1138-D1143. PMC: 7779006. DOI: 10.1093/nar/gkaa891. View

11.

Ruan Z, Lu T, Chen Y, Yuan M, Yu H, Liu R . Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults. JAMA Dermatol. 2022; 158(7):745-753. PMC: 9134040. DOI: 10.1001/jamadermatol.2022.1609. View

12.

Duell P, Welty F, Miller M, Chait A, Hammond G, Ahmad Z . Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022; 42(6):e168-e185. DOI: 10.1161/ATV.0000000000000153. View

13.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

14.

Huang D, El-Serag H, Loomba R . Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020; 18(4):223-238. PMC: 8016738. DOI: 10.1038/s41575-020-00381-6. View

15.

Deng Y, Pan M, Nie H, Zheng C, Tang K, Zhang Y . Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats. Molecules. 2019; 24(21). PMC: 6864612. DOI: 10.3390/molecules24213943. View

16.

Jinnouchi H, Guo L, Sakamoto A, Torii S, Sato Y, Cornelissen A . Diversity of macrophage phenotypes and responses in atherosclerosis. Cell Mol Life Sci. 2019; 77(10):1919-1932. PMC: 11104939. DOI: 10.1007/s00018-019-03371-3. View

17.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

18.

Li L, Huang Q, Yang L, Zhang R, Gao L, Han X . The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004. Nutrients. 2022; 14(6). PMC: 8948655. DOI: 10.3390/nu14061224. View

19.

Lluch A, Veiga S, Latorre J, Moreno-Navarrete J, Bonifaci N, Nguyen V . A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis. JCI Insight. 2022; 7(14). PMC: 9431684. DOI: 10.1172/jci.insight.150461. View

20.

Tilg H, Effenberger M . From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020; 17(7):387-388. DOI: 10.1038/s41575-020-0316-6. View